Treatment Selection Patterns and Associated Outcomes for Biguanides and SGLT2 Inhibitors in Type 2 Diabetes: A Retrospective Database Study in Japan - Takeaways - MDSpire

Treatment Selection Patterns and Associated Outcomes for Biguanides and SGLT2 Inhibitors in Type 2 Diabetes: A Retrospective Database Study in Japan

  • By

  • Ryo Mishima

  • Daisuke Koide

  • July 13, 2026

Share

  • 1

    Treatment selection for diabetes in Japan is primarily influenced by cardiovascular risk rather than BMI, contrary to current guidelines.

  • 2

    Biguanides demonstrated a significant reduction in HbA1c levels at 24 weeks compared to SGLT2 inhibitors.

  • 3

    SGLT2 inhibitors showed higher treatment persistence over 48 weeks in the first-line treatment cohort.

  • 4

    The study utilized a retrospective cohort design, analyzing data from the Millennium Medical Record Database in Japan.

  • 5

    Biguanides and SGLT2 inhibitors are increasingly prescribed in Japan, reflecting a shift away from the previously dominant DPP-4 inhibitors.

Original Source(s)

Treatment Selection Patterns and Associated Outcomes for Biguanides and SGLT2 Inhibitors in Type 2 Diabetes: A Retrospective Database Study in Japan

  • by Ryo Mishima, Daisuke Koide

  • July 13, 2026

Related Content

Association of four non-insulin-based insulin resistance surrogate markers with colorectal cancer risk: a large-scale prospective cohort study using the UK Biobank

A network meta-analysis of endocrine adverse events induced by immune checkpoint inhibitors in colorectal cancer

Sport: The Precision Medicine Vanguard

Armed with ever-more practical and powerful sampling devices, omics workflows, and wearable tech, could elite athletes pioneer a more precise approach to sport – and health?